Guidance increased, but Medicaid utilization remains elevated and portfolio exits underscore ongoing execution risk [4][55].
| Quarter | Q2 FY26 |
|---|---|
| Call date | 2026-07-15 |
| Length | 64 minutes |
| EPS | $7.45 |
| EPS consensus | $6.18 |
| Revenue | $50.5B |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q1 FY26 · Q4 FY25 · Q3 FY25 · Q2 FY25 · Q1 FY25
All ELV earnings · Back to ELV overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.